NDA 205525 · Wellhouse Pharma
Syndros
Dronabinol · Oral · Cannabinoid
DiscontinuedLast checked: Nov 20, 2026Latest source record: May 17, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Jul 1, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
354
68 Phase 3, 52 recruiting
FAERS reports
5,133
3,836 serious, 1,169 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 21, 2026.
SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. SYNDROS is a cannabinoid indicated in adults for the treatment of: anorexia associated with weight loss in patients with AIDS. ( 1 ) nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. ( 1 )
Mechanism: Dronabinol is an orally active cannabinoid that has complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors may play a role in mediating the effects of dronabinol.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 1, 2016 Original approval · Type 3 - New Dosage Form LabelLetterFederal Register Notice
1 products under this application
- SYNDROS · DRONABINOL 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Dronabinol" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral RadiculopathyPivotal-lookingRecruiting
Vertanical GmbHIndustry
NCT06956014 · 810 participants (planned) · Start Sep 22, 2026 · Primary completion Sep 2028
Drug: VER-01 · For: Lumbosacral Radiculopathy
Sites: Mobile, Alabama; Tempe, Arizona; Long Beach, California · 43 sites in all
- Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related PainPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT01337089 · 660 participants · Start Jan 19, 2011 · Primary completion Jan 27, 2016
Drug: Nabiximols · For: Pain; Advanced Cancer
Sites: Phoenix, Arizona; El Cajon, California; Gilroy, California · 128 sites in all
- Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back PainPivotal-lookingCompleted
Vertanical GmbHIndustry
NCT06475001 · 652 participants · Start Jun 28, 2024 · Primary completion Jul 31, 2025
Drug: VER-01; Placebo · For: Chronic Non-specific Low Back Pain
Sites: London, United Kingdom
- A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00681538 · 572 participants · Start Jan 2008 · Primary completion Jan 2009
Drug: Sativex®; Placebo · For: Spasticity; Multiple Sclerosis
Sites: Cliftonville, United Kingdom
- Efficacy and Tolerability of AP707 in Patients With Chronic Back PainPivotal-lookingStatus unknown
Apurano Pharmaceuticals GmbHIndustry
NCT06072560 · 558 participants (planned) · Start Nov 2, 2023 · Primary completion Sep 30, 2024
Drug: Adezunap (AP707); Placebo · For: Pain; Pain Syndrome; Pain, Chronic and 5 more
Sites: Munich, Germany
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic PolyneuropathyPivotal-lookingStatus unknown
Apurano Pharmaceuticals GmbHIndustry
NCT06071975 · 558 participants (planned) · Start Nov 2, 2023 · Primary completion Sep 30, 2024
Drug: Adezunap (AP707); Placebo · For: Pain; Pain Syndrome; Pain, Chronic and 8 more
Sites: Munich, Germany
- Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any GenesisPivotal-lookingStatus unknown
Apurano Pharmaceuticals GmbHIndustry
NCT06071949 · 558 participants (planned) · Start Nov 2, 2023 · Primary completion Sep 30, 2024
Drug: Adezunap; Placebo · For: Pain; Pain Syndrome; Pain, Chronic and 10 more
Sites: Munich, Germany
- Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral NeuropathyPivotal-lookingStatus unknown
Apurano Pharmaceuticals GmbHIndustry
NCT06071988 · 558 participants (planned) · Start Nov 2, 2023 · Primary completion Sep 30, 2024
Drug: Adezunap (AP707); Placebo · For: Pain; Pain Syndrome; Pain, Chronic and 9 more
Sites: Munich, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea485
- fatigue420
- off label use388
- diarrhoea387
- death383
- toxicity to various agents341
- drug abuse309
- vomiting281
- decreased appetite275
- pain253
- weight decreased237
- drug screen positive225
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 16 |
| 2006 | 22 |
| 2007 | 16 |
| 2008 | 16 |
| 2009 | 27 |
| 2010 | 36 |
| 2011 | 58 |
| 2012 | 60 |
| 2013 | 80 |
| 2014 | 136 |
| 2015 | 211 |
| 2016 | 246 |
| 2017 | 338 |
| 2018 | 477 |
| 2019 | 512 |
| 2020 | 439 |
| 2021 | 407 |
| 2022 | 415 |
| 2023 | 465 |
| 2024 | 495 |
| 2025 | 397 |
| 2026 | 252 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.
Bilbao A, Spanagel R · BMC Med 2022 · Meta-Analysis, Systematic Review
- Cannabinoids for the treatment of dementia.
Bosnjak Kuharic D, Markovic D, Brkovic T, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Systematic Review
- Cannabis-associated arteritis.
Grotenhermen F · Vasa 2010 · Systematic Review
- Cannabis-Based Products for Chronic Pain : An Updated Systematic Review.
Chou R, Fu R, Ahmed AY, et al. · Ann Intern Med 2026 · Systematic Review
- Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M, Phillips T, Radbruch L, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G, Minozzi S, Borrelli F, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Wellhouse Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.